CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
REVENUES:
Total Revenues	$ 941	$ 3,924	$ 7,774	$ 9,287
OPERATING EXPENSES:
Research and Development	11,918	21,915	55,242	72,707
General and Administrative	3,722	5,346	14,936	19,109
Goodwill Impairment			90,976
Intangible Asset Impairment		13,000	18,677	13,000
Gain on Fair Value Remeasurement of Contingent Consideration	(6,935)	(4,600)	(27,968)	(200)
Amortization of Acquired Intangible Assets	0	224	224	672
Total Operating Expenses	8,705	35,885	152,087	105,288
Operating Loss	(7,764)	(31,961)	(144,313)	(96,001)
Investment and Other Income, Net	521	398	1,767	1,611
Net Loss Before Income Tax Benefit	(7,243)	(31,563)	(142,546)	(94,390)
Income Tax Benefit		5,200	765	5,200
Net Loss	$ (7,243)	$ (26,363)	$ (141,781)	$ (89,190)
Basic and Diluted Net Loss Per Common Share (in dollars per share)	$ (0.04)	$ (0.20)	$ (0.94)	$ (0.71)
Shares Used in Calculating Basic and Diluted Net Loss Per Share (in shares)	163,679	129,640	150,636	125,856
COMPREHENSIVE LOSS:
Net Loss	$ (7,243)	$ (26,363)	$ (141,781)	$ (89,190)
Other Comprehensive Income (Loss):
Unrealized Gain (Loss) on Marketable Securities	(8)	11	18	47
Comprehensive Loss	(7,251)	(26,352)	(141,763)	(89,143)
Product Development and Licensing Agreements
REVENUES:
Total Revenues	131	1,238	2,792	2,488
Contracts and Grants
REVENUES:
Total Revenues	$ 810	$ 2,686	$ 4,982	$ 6,799